当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Poziotinib Shows Promise for Rare Lung Cancer
Cancer Discovery ( IF 29.7 ) Pub Date : 2018-01-01 , DOI: 10.1158/2159-8290.cd-nb2017-164
American Association for Cancer Research

Poziotinib, an EGFR inhibitor that was previously shelved as ineffective against non–small cell lung cancer, is showing promising activity in a subset of patients with EGFR exon 20 insertions. According to preliminary data from a phase II trial, the drug led to a 73% overall response rate in patients with this disease subtype, which is typically highly resistant to standard therapy.



中文翻译:

Poziotinib有望治疗罕见肺癌

Poziotinib是一种EGFR抑制剂,以前被搁置为对非小细胞肺癌无效,在一部分EGFR外显子20插入患者中显示出有希望的活性。根据来自II期临床试验的初步数据,该药物导致该疾病亚型患者的总体缓解率达到73%,该患者通常对标准疗法有很高的抵抗力。

更新日期:2018-01-08
down
wechat
bug